The generic drug makers trade association, GPHA, has petitioned the FDA to use the SAME international non-proprietary name (INN) for biosimilars as would be used for the reference drug that corresponds to it. This would help promote interachangeability if that had been established.
PhRMA and BIO on the other hand have already made it known to the FDA that they would like to see every biosimilar have a unique non-proprietary name that distinguishes it from the reference biological. This, they say, would allow better pharmaco vigilance and tracking. This would promote safety. This too would likely cut down on interchangeability or at least confuse the issue.
Needless to say, this is a business question. How can I best protect (PhRMA/BIO) or promote (GPHA) my drugs sales once the biosimilar has been approved? No bias here, just vote our pocket book.
Posted by Bruce Lehr Sep 20th 2013.